Ekso Bionics Appoints Thomas Schreck to its Board of Directors
RICHMOND, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced the appointment of Thomas Schreck to its Board of Directors, effective immediately.
“We are pleased to welcome Thomas to our Board,” said Steven Sherman, Chairman of the Board of Ekso Bionics. “With past successes in leading several pharmaceutical and medical device companies, Thomas brings a wealth of experience commercializing innovative solutions that align with our corporate strategy. His unique perspective and insights will enhance our ability to create value for our shareholders, customers, and patients.”
Mr. Schreck is Co-Founder, Vice Chairman and Chief Executive Officer of SinuSys, Inc., a medical device company focused on developing new therapies to improve sinus health. Previously, Mr. Schreck was Co-Founder, Chairman and CEO of AcelRx, Inc., where he and his team co-invented, developed and enabled the commercialization of hand-held solutions for acute and post-operative pain control. Before co-founding AcelRx, he was Co-Founder and CFO of Durect Corporation where he was instrumental in the spin out of the DUROS drug delivery technology from Alza Corporation. He also holds more than 30 U.S. patents. Mr. Schreck received a BA in American Civilization from Williams College.
“Ekso is a leader in innovating exoskeleton systems with capabilities that provide meaningful benefits for the medical and industrial markets,” said Mr. Schreck. “I look forward to working with the Ekso Board and senior leadership team as the company continues to strengthen its position in these growing markets.”
About Ekso Bionics®
Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Founded in 2005, the company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. The company is headquartered in the Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO. For more information, visit: www.eksobionics.com.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) estimates or projection of financial results, financial condition, operating results, capital expenditures, capital structure, continued momentum in commercialization efforts, expansion of product footprint or other financial or operational items, (iii) the Company's future financial performance, and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, changes resulting from the Company’s finalization of its financial statements for and as of the three and nine months ended September 30, 2018, information or new changes in facts or circumstances that may occur prior to the filing of the Company’s Quarterly Report on Form 10-Q for such period that are required to be included therein, the Company's inability to obtain adequate financing to fund the Company's operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of the Company’s sales and marketing organization or partners to market the Company’s products effectively, adverse results in future clinical studies of the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. To learn more about Ekso Bionics please visit us at www.eksobionics.com. The Company does not undertake to update these forward-looking statements.
Investor Contact:
David Carey
212-867-1768
dcarey@lazarpartners.com
Media Contact:
Glenn Silver
646-871-8485
gsilver@lazarpartners.com
Released November 6, 2018